HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
HSPA9
heat shock protein family A (Hsp70) member 9
Chromosome 5 Β· 5q31.2
NCBI Gene: 3313Ensembl: ENSG00000113013.17HGNC: HGNC:5244UniProt: A0A384P5G6
557PubMed Papers
22Diseases
0Drugs
6Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
RNA bindingnegative regulation of erythrocyte differentiationmitochondrial matrixmitochondrioneven-plus syndromeautosomal dominant sideroblastic anemiaConstitutional sideroblastic anemiaautosomal recessive sideroblastic anemia
✦AI Summary

HSPA9 is a mitochondrial Hsp70 chaperone essential for protein quality control, executing ATP-dependent cycles of protein folding, refolding, and degradation 123. It facilitates mitochondrial protein import via the TIM complex and plays a critical role in iron-sulfur cluster biogenesis by stabilizing assembly proteins FXN, NFU1, NFS1, and ISCU, thereby regulating erythropoiesis 45. HSPA9 regulates mitochondrial calcium dynamics by coupling ITPR1 and VDAC1 at mitochondria-associated ER membranes, supporting calcium-dependent apoptosis 6. Beyond mitochondria, cytosolic HSPA9 interacts with signaling and apoptotic proteins, potentially regulating cell cycle through TP53 degradation promotion 78. Extracellular HSPA9 provides cytoprotection against membrane attack complex-mediated lysis 9. Disease relevance is substantial: HSPA9 overexpression associates with glioblastoma immune escape through OMA1-mediated mitophagy and cGAS-STING activation 10, breast cancer progression via KEAP1-regulated mitochondrial biogenesis 11, bladder cancer metastasis through MUL1-mediated nuclear translocation 12, and multiple myeloma bortezomib resistance via exosomal transmission and USP1/TRIP13 signaling 1314. HSPA9 elevation predicts adverse prostate cancer outcomes 15, establishing it as a potential biomarker and therapeutic target across multiple malignancies.

Sources cited
1
HSPA9 regulates mitochondrial calcium dynamics by coupling ITPR1 and VDAC1 at mitochondria-associated ER membranes, supporting calcium-dependent apoptosis .
PMID: 35541901
2
Extracellular HSPA9 provides cytoprotection against membrane attack complex-mediated lysis .
PMID: 16091382
3
Disease relevance is substantial: HSPA9 overexpression associates with glioblastoma immune escape through OMA1-mediated mitophagy and cGAS-STING activation , breast cancer progression via KEAP1-regulated mitochondrial biogenesis , bladder cancer metastasis through MUL1-mediated nuclear translocation , and multiple myeloma bortezomib resistance via exosomal transmission and USP1/TRIP13 signaling , .
PMID: 38604814
4
Disease relevance is substantial: HSPA9 overexpression associates with glioblastoma immune escape through OMA1-mediated mitophagy and cGAS-STING activation , breast cancer progression via KEAP1-regulated mitochondrial biogenesis , bladder cancer metastasis through MUL1-mediated nuclear translocation , and multiple myeloma bortezomib resistance via exosomal transmission and USP1/TRIP13 signaling , .
PMID: 39003742
5
Disease relevance is substantial: HSPA9 overexpression associates with glioblastoma immune escape through OMA1-mediated mitophagy and cGAS-STING activation , breast cancer progression via KEAP1-regulated mitochondrial biogenesis , bladder cancer metastasis through MUL1-mediated nuclear translocation , and multiple myeloma bortezomib resistance via exosomal transmission and USP1/TRIP13 signaling , .
PMID: 39113711
6
HSPA9 elevation predicts adverse prostate cancer outcomes , establishing it as a potential biomarker and therapeutic target across multiple malignancies.
PMID: 34717191
Disease Associationsβ“˜22
even-plus syndromeOpen Targets
0.76Strong
autosomal dominant sideroblastic anemiaOpen Targets
0.65Moderate
Constitutional sideroblastic anemiaOpen Targets
0.65Moderate
autosomal recessive sideroblastic anemiaOpen Targets
0.37Weak
sideroblastic anemiaOpen Targets
0.37Weak
atrial fibrillationOpen Targets
0.37Weak
schizophreniaOpen Targets
0.25Weak
neurodegenerative diseaseOpen Targets
0.25Weak
genetic disorderOpen Targets
0.19Weak
secondary malignant neoplasmOpen Targets
0.19Weak
neoplasmOpen Targets
0.11Weak
hepatocellular carcinomaOpen Targets
0.11Weak
breast cancerOpen Targets
0.10Weak
cancerOpen Targets
0.10Weak
ovarian cancerOpen Targets
0.10Suggestive
Miyoshi myopathyOpen Targets
0.09Suggestive
medullary thyroid gland carcinomaOpen Targets
0.09Suggestive
lung adenocarcinomaOpen Targets
0.09Suggestive
KeloidOpen Targets
0.08Suggestive
intrahepatic cholangiocarcinomaOpen Targets
0.08Suggestive
Anemia, sideroblastic, 4UniProt
Even-plus syndromeUniProt
Pathogenic Variants6
NM_004134.7(HSPA9):c.1728+2T>GLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2020
NM_004134.7(HSPA9):c.955C>T (p.Leu319Phe)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2020β†’ Residue 319
NM_004134.7(HSPA9):c.818T>G (p.Leu273Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2020β†’ Residue 273
NM_004134.7(HSPA9):c.409_410del (p.Asp136_Ile137insTer)Pathogenic
Autosomal dominant sideroblastic anemia
β˜†β˜†β˜†β˜†2017β†’ Residue 136
NM_004134.7(HSPA9):c.376C>T (p.Arg126Trp)Pathogenic
Even-plus syndrome
β˜†β˜†β˜†β˜†2017β†’ Residue 126
NM_004134.7(HSPA9):c.383A>G (p.Tyr128Cys)Pathogenic
Even-plus syndrome
β˜†β˜†β˜†β˜†2017β†’ Residue 128
View on ClinVar β†—
Related Genes
DNAJB2Protein interaction100%TIMM50Protein interaction100%TLR6Protein interaction100%TLR1Protein interaction100%TLR4Protein interaction100%TIMM17AProtein interaction100%
Tissue Expression6 tissues
Heart
100%
Liver
92%
Bone Marrow
83%
Brain
68%
Ovary
42%
Lung
37%
Gene Interaction Network
Click a node to explore
HSPA9DNAJB2TIMM50TLR6TLR1TLR4TIMM17A
PROTEIN STRUCTURE
Preparing viewer…
PDB6P2U Β· 2.00 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.53Moderately Constrained
pLIβ“˜
0.86Intermediate
Observed/Expected LoF0.38 [0.27–0.53]
RankingsWhere HSPA9 stands among ~20K protein-coding genes
  • #438of 20,598
    Most Researched557 Β· top 5%
  • #3,286of 5,498
    Most Pathogenic Variants6
  • #3,261of 17,882
    Most Constrained (LOEUF)0.53 Β· top quartile
Genes detectedHSPA9
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape.
PMID: 38604814
J Immunother Cancer Β· 2024
1.00
2
GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients.
PMID: 35541901
Int J Biol Sci Β· 2022
0.90
3
Artesunate induces ferroptosis in gastric cancer by targeting the TFRC-HSPA9 axis for iron homeostasis regulation.
PMID: 40946428
Redox Biol Β· 2025
0.84
4
The Wolfram-like variant WFS1
PMID: 38651637
Autophagy Β· 2024
0.80
5
Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer.
PMID: 39003742
Cell Rep Β· 2024
0.80